API | lerisetron

lerisetron Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT3 receptor. It is a potent antiemetic and was in clinical trials for the treatment of nausea associated with cancer chemotherapy. ^Wikipedia

Chemistry

SMILES: c1ccc(Cn2c(N3CCNCC3)nc3ccccc32)cc1
InChIKey: PWWDCRQZITYKDV-UHFFFAOYSA-N
Mol. Mass: 292.39
ALogP: 2.49 Partition coefficient
ChEMBL Molecule:
lerisetron

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 3A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1-benzyl-2-(1-piperazinyl)benzimidazole | lerisetron

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Nausea (Phase 3)

Testicular Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue